Verrica Pharmaceuticals announced the dosing of the first U.S. patient in the Phase 3 COVE-3 trial for YCANTH in treating common warts, while its partner Torii Pharmaceutical dosed the first Japanese patient in the same trial last week. Common warts affect roughly 22 million people in the U.S. alone, with half of patients being children. YCANTH is a drug-device combination product previously approved by the FDA in 2023 for molluscum contagiosum. The COVE-3 trial is the second of two double-blind, randomized, vehicle-controlled studies in the Phase 3 program, with the first, COVE-2, having completed 50% enrollment last month. Trial costs are split evenly between Torii and Verrica, with Torii responsible for the first $40 million.
Verrica Pharmaceuticals IncDosing of first patient in Phase 3 COVE-3 trial for YCANTH in common warts, advancing clinical development.
Partner Torii dosed first Japanese patient in same trial, sharing costs and development responsibilities.